Breaking News Instant updates and real-time market news.

AMAG

Amag Pharmaceuticals

$21.63

1.31 (6.45%)

08:12
10/04/18
10/04
08:12
10/04/18
08:12

Amag Pharmaceuticals to present data on Intrarosa at NAMS

Amag Pharmaceutical and Endoceutics announced an oral presentation regarding the effect of time since menopause, age, and previous hormone therapy on treatment efficacy of intravaginal 6.5 mg prasterone at the Annual Meeting of The North American Menopause Society, or NAMS. David Archer and colleagues analyzed combined data obtained from two prospective, randomized, double-blind, placebo-controlled clinical trials to evaluate the effect of daily intravaginal 6.5 mg Intrarosa administered for 12 weeks to women who identified moderate to severe pain at sexual activity as their most bothersome symptom, or MBS, of vulvar and vaginal atrophy, or VVA. The goal of the analysis was to assess the potential influence of time since menopause, age and previous hormone therapy on the response to treatment. Overall, there were 406 women treated with 6.5 mg Intrarosa and 234 women who received placebo. Women were divided into subgroups based upon time since menopause, age and if they had ever taken hormone therapy. While age and prior hormone therapy did not influence the overall efficacy of Intrarosa, the greatest reduction of dyspareunia had a tendency to be observed in women who were 1-2 years post menopause, compared to 3-5 years and more than 6 years post menopause, although the difference did not reach statistical significance.

  • 27

    Nov

  • 23

    Mar

AMAG Amag Pharmaceuticals
$21.63

1.31 (6.45%)

09/26/18
PIPR
09/26/18
NO CHANGE
PIPR
Neutral
Piper says Amag goal to add 174 patients to trial by 2019 'may be a tall order'
Piper Jaffray analyst Christopher Raymond noted that Amag Pharmaceuticals announced it has taken over development of digoxin immune Fab for the treatment of severe preeclampsia from Velo Bio and seeks to add an additional 174 patients by the end of 2019, which he believes "may be a tall order." As he waits to see how enrollment progresses for this trial, he continues to have concerns with Amag's current franchise as Makena, which makes up over 70% of revenue, recently began facing generic competition, Raymond tells investors. The analyst maintains a Neutral rating on Amag shares and says he is still "comfortable on the sidelines."
08/02/18
PIPR
08/02/18
NO CHANGE
Target $22
PIPR
Neutral
Piper 'comfortable' on sidelines of Amag given generic Makena risk
Piper Jaffray analyst Christopher Raymond said Amag Pharmaceuticals reported strong results for both Makena and Feraheme along with an "impressive" EBITDA beat in Q2, but he remains comfortable on the sidelines given that multiple Makena generic entrants are expected in the second half of this year. Raymond raised his price target on Amag shares to $22 from $20 but keeps a Neutral rating on the stock.
06/25/18
PIPR
06/25/18
NO CHANGE
Target $20
PIPR
Neutral
Piper Jaffray remains on sidelines after AMAG indicates launch of generic Makena
Piper Jaffray analyst Christopher Raymond maintained a Neutral rating and $20 price target on AMAG Pharmaceuticals after the company announced this morning that it intends to launch an authorized generic of Makena through generic manufacturer Prasco Laboratories, adding that Makena's loss of exclusivity "is now upon us." While he contends that the timing of the generic's approval "should surprise nobody," Raymond says this serves as a reminder to investors that a key threat to the business is now underway and remains on the sidelines. The analyst continues to model Makena revenue of $302M, $178M, $92M, and $29M for 2018-2021, adding that "the trajectory doesn't look pretty."
06/15/18
06/15/18
UPGRADE
Target $30

Buy
Amag Pharmaceuticals upgraded to Buy after deal to sell CBR at B. Riley FBR
As previously reported, B. Riley FBR analyst David Buck upgraded Amag Pharmaceuticals to Buy from Neutral after the company agreed to sell Cord Blood Registry to private equity firm GI Partners for $530M in cash. The divestiture should allow the company to retire senior debt and become net debt free, which would eliminate his concern about Amag being highly-leveraged, Buck tells investors. Despite the "negative optics" of selling for below the $700M it paid to buy CBR, Buck sees the choice to divest as strategically sound, the analyst added. He raised his price target on Amag shares to $30 from $23, citing switching to Makena auto-injector, growth for Intrarosa and an early 2019 FDA approval for bremalanotide as key catalysts.

TODAY'S FREE FLY STORIES

LQDA

Liquidia Technologies

$5.23

-0.38 (-6.77%)

16:35
08/23/19
08/23
16:35
08/23/19
16:35
Syndicate
Breaking Syndicate news story on Liquidia Technologies »

Liquidia Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$175.24

-4.91 (-2.73%)

16:32
08/23/19
08/23
16:32
08/23/19
16:32
Hot Stocks
Visa CFO Prabhu sells over 25,000 class A common shares »

Visa vice chairman and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 27

    Oct

QCOM

Qualcomm

$73.57

-3.55 (-4.60%)

16:31
08/23/19
08/23
16:31
08/23/19
16:31
Hot Stocks
Qualcomm CFO Dave Wise to retire, Akash Palkhiwala named interim CFO »

Qualcomm announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 06

    Nov

ANFI

Amira Nature Foods

$0.58

-0.0144 (-2.44%)

16:30
08/23/19
08/23
16:30
08/23/19
16:30
Hot Stocks
Amira Nature Foods receives NYSE notice over late Form 20-F filing »

Amira Nature Food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
08/23/19
08/23
16:30
08/23/19
16:30
Options
Preliminary option volume of 26.7M today »

Preliminary option volume…

DXCM

DexCom

$173.45

-0.76 (-0.44%)

16:26
08/23/19
08/23
16:26
08/23/19
16:26
Hot Stocks
Court rules patents asserted against DexCom CGM systems are invalid »

The U.S. District Court…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 09

    Sep

  • 13

    Nov

CRM

Salesforce

$151.50

3.24 (2.19%)

, VMW

VMware

$133.43

-14.72 (-9.94%)

16:24
08/23/19
08/23
16:24
08/23/19
16:24
On The Fly
Fly Intel: Wall Street's top stories for Friday »

The stock market was…

CRM

Salesforce

$151.50

3.24 (2.19%)

VMW

VMware

$133.43

-14.72 (-9.94%)

PVTL

Pivotal Software

$14.86

1.17 (8.55%)

CBLK

Carbon Black

$26.05

1.525 (6.22%)

HAS

Hasbro

$104.16

-10.19 (-8.91%)

HPQ

HP Inc.

$17.81

-1.1 (-5.82%)

QCOM

Qualcomm

$73.57

-3.55 (-4.60%)

SBGI

Sinclair Broadcast

$43.10

-1.33 (-2.99%)

DIS

Disney

$131.70

-4.37 (-3.21%)

T

AT&T

$34.82

-0.57 (-1.61%)

QD

Qudian

$7.86

0.21 (2.75%)

INTU

Intuit

$278.53

2.48 (0.90%)

FL

Foot Locker

$34.00

-8 (-19.05%)

ATGE

Adtalem Global Education

$44.82

-6.11 (-12.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 28

    Aug

  • 28

    Aug

  • 04

    Sep

  • 04

    Sep

  • 05

    Sep

  • 05

    Sep

  • 06

    Sep

  • 10

    Sep

  • 10

    Sep

  • 11

    Sep

  • 19

    Sep

  • 23

    Sep

  • 25

    Sep

  • 10

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

  • 12

    Dec

  • 16

    Dec

BMCH

BMC Stock Holdings

$24.79

-0.62 (-2.44%)

16:24
08/23/19
08/23
16:24
08/23/19
16:24
Syndicate
Breaking Syndicate news story on BMC Stock Holdings »

BMC Stock Holdings files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 13

    Nov

MRVL

Marvell

$23.79

-1.01 (-4.07%)

16:20
08/23/19
08/23
16:20
08/23/19
16:20
Options
Five 5 minute put seller in Marvell Technology »

Five 5 minute put seller…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 10

    Sep

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
08/23/19
08/23
16:20
08/23/19
16:20
Options
Closing CBOE SPX and VIX Index summary for August 23rd »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:20
08/23/19
08/23
16:20
08/23/19
16:20
General news
Treasury Market Summary »

Treasury Market Summary:…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
08/23/19
08/23
16:17
08/23/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
08/23/19
08/23
16:16
08/23/19
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NK

NantKwest

$1.29

-0.05 (-3.73%)

16:12
08/23/19
08/23
16:12
08/23/19
16:12
Syndicate
Breaking Syndicate news story on NantKwest »

NantKwest files $300M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WISA

Summit Wireless

$1.14

-0.04 (-3.39%)

16:10
08/23/19
08/23
16:10
08/23/19
16:10
Syndicate
Breaking Syndicate news story on Summit Wireless »

Summit Wireless files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLF

Tandy Leather

$4.60

-0.08 (-1.71%)

16:10
08/23/19
08/23
16:10
08/23/19
16:10
Hot Stocks
Tandy Leather receives noncompliance notice from Nasdaq »

Tandy Leather received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSPR

InspireMD

$2.90

0.1 (3.57%)

16:09
08/23/19
08/23
16:09
08/23/19
16:09
Syndicate
Breaking Syndicate news story on InspireMD »

InspireMD files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SITO

Sito Mobile

$0.77

-0.0189 (-2.41%)

16:08
08/23/19
08/23
16:08
08/23/19
16:08
Hot Stocks
Sito Mobile discloses Nasdaq notice of listing deficiency »

SITO Mobile has received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVA

Avista

$46.05

-0.96 (-2.04%)

16:06
08/23/19
08/23
16:06
08/23/19
16:06
Hot Stocks
Avista files PGA request with Idaho PUC »

Avista its Purchased Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$110.98

-4.22 (-3.66%)

, FDX

FedEx

$152.18

-5.93 (-3.75%)

16:03
08/23/19
08/23
16:03
08/23/19
16:03
Periodicals
FedEx says already seeking to stop illegal drug shipments, Reuters says »

Joining its rival United…

UPS

UPS

$110.98

-4.22 (-3.66%)

FDX

FedEx

$152.18

-5.93 (-3.75%)

AMZN

Amazon.com

$1,748.03

-55.97 (-3.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 17

    Sep

  • 17

    Sep

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

  • 27

    Oct

  • 13

    Nov

STZ

Constellation Brands

$198.38

-3.11 (-1.54%)

15:55
08/23/19
08/23
15:55
08/23/19
15:55
Options
Constellation Brands put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

NFLX

Netflix

$291.26

-5.61 (-1.89%)

15:53
08/23/19
08/23
15:53
08/23/19
15:53
Periodicals
Netflix testing new method of human-driven curation, TechCrunch says »

Netflix is testing a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

KEY

KeyCorp

$16.06

-0.51 (-3.08%)

15:45
08/23/19
08/23
15:45
08/23/19
15:45
Options
KeyCorp call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 17

    Oct

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

15:37
08/23/19
08/23
15:37
08/23/19
15:37
General news
Dow at session lows, decline extends to over 600 points »

At time of writing, the…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

NDX

Nasdaq 100 Index

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$285.73

-6.63 (-2.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBT

BB&T

$45.62

-1.05 (-2.25%)

15:35
08/23/19
08/23
15:35
08/23/19
15:35
Options
BB&T put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

  • 06

    Sep

  • 17

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.